Position in ABBV
as of Jun 30, 2026
· filed Jul 28, 2026
Position Value
$776,812
+$153,486 QoQ
Shares Held
3,087
+7.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.90%
of 13F equity value
Holder Rank
#2,785
of 4,150 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026American Capital Advisory, LLC holds $3,468,342 across 15 Drug Manufacturers - General names. ABBV ranks #2 (22.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
6,146 | $789,761 | |
| 2 | ABBV |
AbbVie Inc.
This page
|
3,087 | $776,812 | |
| 3 | LLY |
ELI LILLY & Co
|
519 | $622,504 | |
| 4 | JNJ |
Johnson & Johnson
|
2,226 | $565,337 | |
| 5 | AMGN |
Amgen Inc
|
921 | $333,512 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
2,414 | $139,094 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
985 | $124,444 | |
| 8 | PFE |
Pfizer Inc
|
2,842 | $68,435 |
All Filings in ABBV
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $776,812 | 3,087 | Shares | Sole | 2026-07-28 | |
| 2026-03-31 | $623,326 | 2,866 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $650,511 | 2,847 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $656,415 | 2,835 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $526,232 | 2,835 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $590,008 | 2,816 | Shares | Sole | 2025-04-28 | |
| 2024-12-31 | $486,009 | 2,735 | Shares | Sole | 2025-01-28 | |
| 2024-09-30 | $540,107 | 2,735 | Shares | Sole | 2024-10-30 | |
| 2024-06-30 | $469,107 | 2,735 | Shares | Sole | 2024-07-29 | |
| 2024-03-31 | $498,043 | 2,735 | Shares | Sole | 2024-04-29 | |
| 2023-12-31 | $423,842 | 2,735 | Shares | Sole | 2024-04-09 | |
| No filing history on record for this holder in this stock. | ||||||